Filing Analysis
Rockwell Medical, Inc. has filed an 8-K to furnish an updated corporate presentation dated August 13, 2026. This is a routine disclosure under Item 7.01 (Regulation FD Disclosure) and does not contain material financial changes or structural shifts.
📋 Key Facts
- The company released an updated corporate presentation on August 13, 2026.
- The filing was made pursuant to Regulation FD Disclosure requirements.
- Information in Exhibit 99.1 is furnished rather than filed, limiting liability under Section 18 of the Exchange Act.
Rockwell Medical, Inc. filed an 8-K to announce its financial results for the quarterly period ended June 30, 2026. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The company issued a press release (Exhibit 99.1) containing the financial results.
- CEO Mark Strobeck signed the report.
Rockwell Medical, Inc. has received notification from Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement. The company is no longer under threat of delisting regarding this specific rule.
🚩 Red Flags
- Historical context of delisting risk (the company was previously non-compliant with minimum bid price requirements).
📋 Key Facts
- Received written notification on July 16, 2026, regarding Nasdaq compliance.
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price requirement).
- Nasdaq considers the specific compliance matter closed.
Rockwell Medical, Inc. is implementing a 1-for-10 reverse stock split effective July 1, 2026. The move was approved by stockholders during the annual meeting held on June 12, 2026.
🚩 Red Flags
- Reverse stock split (often used to avoid Nasdaq delisting due to low share price).
- No mention of specific financial distress in the text, but reverse splits are frequently a precursor or response to non-compliance with minimum bid requirements.
📋 Key Facts
- Reverse stock split ratio: 1-for-10.
- Effective date/time: July 1, 2026, at 12:01 a.m. ET.
- New CUSIP number: 774374409.
- Trading symbol 'RMTI' remains unchanged on Nasdaq Capital Market.
- Fractional shares will be paid out in cash based on the closing price on June 30, 2026.
- Proportionate adjustments will apply to equity plans, Series X Convertible Preferred Stock conversion prices, and outstanding warrants.
Rockwell Medical held its 2026 Annual Meeting of Stockholders on June 12, 2026, where shareholders approved several proposals, most notably an amendment to the Certificate of Incorporation to effect a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is a significant red flag for micro-cap companies, often indicating a struggle to maintain minimum bid price requirements for exchange listing (Nasdaq Capital Market).
📋 Key Facts
- Annual Meeting of Stockholders held on June 12, 2026.
- Proposal Four (Reverse Stock Split) was approved with 16,993,038 votes 'For' and 6,597,036 votes 'Against'.
- Proposal Three ratified EisnerAmper LLP as the independent registered public accounting firm for 2026.
- Proposal One elected Joseph Dawson and Joan Lau, Ph.D. as Class II directors.
- Proposal Two (Executive Compensation) was approved on an advisory basis.
Rockwell Medical, Inc. received a Nasdaq deficiency notice on May 8, 2026, for failing to maintain the $1.00 minimum bid price for 30 consecutive business days. The company has until November 4, 2026, to regain compliance and intends to seek shareholder approval for a reverse stock split to address the deficiency.
🚩 Red Flags
- Nasdaq delisting notice for minimum bid price deficiency.
- Proposed reverse stock split to artificially inflate share price.
- Sustained period (30+ days) of the stock trading below $1.00.
📋 Key Facts
- Received Nasdaq notice on May 8, 2026, regarding non-compliance with Listing Rule 5550(a)(2).
- The common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days.
- The company has an initial 180-calendar day grace period, ending November 4, 2026, to regain compliance.
- Compliance requires the stock price to close at or above $1.00 for at least 10 consecutive business days.
- The company has already included a proposal for a reverse stock split in its 2026 Annual Meeting Proxy Statement.
Rockwell Medical, Inc. furnished an updated corporate presentation on May 7, 2026, as part of a routine Regulation FD disclosure. The presentation is intended to provide current information to investors and stakeholders.
📋 Key Facts
- The filing was made on May 7, 2026, under Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains the updated corporate presentation dated May 7, 2026.
- The information is 'furnished' rather than 'filed', meaning it is not subject to the same liability standards as filed documents under Section 18 of the Exchange Act.
- The report was signed by Mark Strobeck, the Chief Executive Officer.
Rockwell Medical, Inc. reported its financial results for the first quarter ended March 31, 2026. The results were disclosed through a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report was filed on May 7, 2026, which is also the date of the earliest event reported.
- The filing covers financial results for the fiscal quarter ended March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full press release regarding the financial results.
Rockwell Medical, Inc. furnished an updated corporate presentation on March 26, 2026, for investor relations purposes. The filing is a standard disclosure under Regulation FD and does not report any material changes to the company's financial condition or operations.
📋 Key Facts
- The filing was made on March 26, 2026, under Item 7.01 (Regulation FD Disclosure).
- An updated corporate presentation was included as Exhibit 99.1.
- The information in the filing is 'furnished' and not 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by CEO Mark Strobeck.
Rockwell Medical, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The results were disclosed via a press release furnished with the filing on March 26, 2026.
📋 Key Facts
- The filing reports financial results for the period ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued on March 26, 2026.
- The filing was signed by CEO Mark Strobeck.
Rockwell Medical, Inc. issued a press release announcing preliminary, unaudited financial results for the quarter and fiscal year ended December 31, 2025.
🚩 Red Flags
- Preliminary results are unaudited and subject to change upon final audit.
📋 Key Facts
- Announced preliminary, unaudited financial results for Q4 and FY 2025 on January 20, 2026.
- Results are subject to completion of quarter-end/year-end closing procedures and audit by independent accounting firm.
- The filing is pursuant to Item 2.02 regarding Results of Operations and Financial Condition.
Rockwell Medical, Inc. has entered into a second amendment to its Products Purchase Agreement with DaVita, Inc., extending the contract term by one year until December 31, 2026. The amendment also includes provisions for an increase in product pricing for the extension period.
🚩 Red Flags
- The filing does not explicitly state if the price increase is sufficient to offset inflationary pressures or if it was a requirement for the extension.
📋 Key Facts
- Counterparty: DaVita, Inc.
- Amendment type: Second Amendment to the Amended and Restated Products Purchase Agreement.
- Extension Term: Contract extended by one year to December 31, 2026.
- Pricing Change: The amendment provides for a price increase on products sold under the agreement during the extension term.
- Effective Date of Amendment: December 23, 2025.
Rockwell Medical, Inc. announced a change in its Board of Directors effective November 17, 2025. Andrea Heslin Smiley resigned from the Board and all committees, while Joseph H. Dawson was appointed as a Class II director.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Andrea Heslin Smiley resigned from the Board of Directors and all committees, effective Nov 17, 2025.
- The company stated Ms. Smiley's resignation was not due to any disagreement regarding operations, policies, or practices.
- Joseph H. Dawson appointed to the Board as a Class II director and member of the Nominating Committee, effective Nov 17, 2025.
- Mr. Dawson previously served as President, North America of Nipro Medical Corporation (May 2013 - June 2025).
- Compensation for Mr. Dawson includes a $45,000 annual cash retainer and $5,000 for committee service.
- Equity awards granted to Mr. Dawson: option for 25,000 shares and 25,000 restricted stock units (RSUs), vesting Nov 17, 2026.
Rockwell Medical, Inc. has filed an 8-K to furnish an updated corporate presentation dated November 12, 2025.
📋 Key Facts
- The company released an updated corporate presentation (Exhibit 99.1) on November 12, 2025.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Information in the exhibit is furnished rather than filed, limiting liability under Section 18 of the Exchange Act.
Rockwell Medical, Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings results (Item 2.02).
- Financial results pertain to the quarter ending September 30, 2025.
- Press release issued on November 12, 2025, is attached as Exhibit 99.1.
Rockwell Medical, Inc. announced the appointment of Heather Hunter as Senior Vice President and Chief Operating Officer, effective September 23, 2025. Ms. Hunter previously served as the company's Senior Vice President and Chief Corporate Affairs Officer.
📋 Key Facts
- Heather Hunter appointed SVP and COO effective September 23, 2025.
- Ms. Hunter's annualized base salary is $323,574 (subject to adjustment).
- Target annual bonus opportunity is 45% of base salary.
- Employment agreement includes provisions for accelerated vesting of time-based awards upon termination due to death or disability, or without cause/for good reason.
- Initial equity grant included up to 60,000 shares of common stock via a time-based option issued outside the 2018 Long-Term Incentive Plan.
Rockwell Medical, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- Reporting date: August 14, 2025
- Period covered: Quarter ended June 30, 2025
- The company issued a press release (Exhibit 99.1) containing the financial results.
- CEO Mark Strobeck signed the report.
Rockwell Medical, Inc. held its 2025 Annual Meeting of Stockholders on May 20, 2025. The filing reports the voting results for director elections, executive compensation, auditor ratification, and an amendment to the Long Term Incentive Plan.
🚩 Red Flags
- The proposal to increase the Long Term Incentive Plan share reserve by 5,000,000 shares represents potential future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on May 20, 2025.
- John G. Cooper and Allen Nissenson, MD were elected to Class I directors for three-year terms expiring in 2028.
- EisnerAmper LLP was ratified as the independent registered public accounting firm for 2025 with significant support (21,767,571 'For' votes).
- Stockholders approved an amendment to the 2018 Long Term Incentive Plan, which includes increasing the share reserve by 5,000,000 shares.
- Advisory vote on executive compensation (Say-on-Pay) was passed with a majority of 'For' votes.
Rockwell Medical, Inc. has filed an 8-K to furnish an updated corporate presentation dated May 12, 2025.
📋 Key Facts
- The company furnished an updated corporate presentation as Exhibit 99.1.
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- The report is signed by CEO Mark Strobeck.
Rockwell Medical, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2025. The filing serves as a formal mechanism to furnish the earnings press release via Exhibit 99.1.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
- Signed by Mark Strobeck, Chief Executive Officer.
Rockwell Medical, Inc. has filed an 8-K to furnish an updated corporate presentation dated March 20, 2025.
📋 Key Facts
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- An updated corporate presentation was released on March 20, 2025, as Exhibit 99.1.
- The information provided in the presentation is furnished rather than filed, meaning it is not subject to the liabilities of Section 18 of the Exchange Act.
Rockwell Medical, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ending December 31, 2024.
📋 Key Facts
- Report date: March 20, 2025
- Reporting period: Quarter and year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18.
Rockwell Medical, Inc. announced the appointment of Jesse Neri as Senior Vice President and Chief Financial Officer (CFO) and Principal Financial Officer, effective December 10, 2024.
🚩 Red Flags
- Equity grants issued outside of the stockholder-approved 2018 Long-Term Incentive Plan (per Nasdaq Rule 5635(c)(4)).
📋 Key Facts
- Jesse Neri appointed as SVP and CFO/Principal Financial Officer on Dec 10, 2024.
- Neri previously served as SVP of Finance (since Oct 2023) and Principal Accounting Officer (since Jan 2024).
- Annualized base salary is $300,000 with a target bonus opportunity of 45%.
- Initial equity grant includes up to 75,000 time-based options issued outside the standard 2018 Long-Term Incentive Plan.
- Employment agreement includes severance provisions for termination without cause or for good reason.
Rockwell Medical, Inc. has filed a prospectus supplement to initiate an aggregate offering of up to $25,000,000 in common stock under an existing controlled equity offering sales agreement with Cantor Fitzgerald & Co.
🚩 Red Flags
- Potential dilution for existing shareholders due to the $25M common stock offering.
- The use of a 'Controlled Equity Offering' often implies an at-the-market (ATM) style program which can create downward price pressure during sales.
📋 Key Facts
- The company is utilizing a new shelf registration statement (Form S-3) that replaced a prior version on October 21, 2024.
- The offering amount is up to $25,000,000 of common stock.
- The sale is being conducted via a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. dated April 8, 2022.
- Legal opinion from Gibson, Dunn & Crutcher LLP was filed as part of this report.
Rockwell Medical, Inc. filed an 8-K to furnish an updated corporate presentation dated November 12, 2024. This is a routine disclosure under Item 7.01 (Regulation FD Disclosure) and does not contain material news or financial changes.
📋 Key Facts
- The company released an updated corporate presentation on November 12, 2024.
- Information was furnished pursuant to Regulation FD Disclosure requirements.
- The filing includes Exhibit 99.1 (Corporate Presentation) and Exhibit 104 (XBRL data).
Rockwell Medical, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period covered: Quarter ended September 30, 2024
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 104 (Interactive Data File)
- CEO Mark Strobeck signed the report
Rockwell Medical, Inc. filed an 8-K to furnish an updated corporate presentation dated August 8, 2024.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- An updated corporate presentation was made available on August 8, 2024.
- The information in the presentation is furnished under General Instruction B.2 and is not deemed 'filed' for purposes of Section 18 liability.
Rockwell Medical, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended June 30, 2024.
📋 Key Facts
- Company issued a press release announcing financial results for the quarter ended June 30, 2024.
- The filing was made on August 8, 2024.
- Financial results are provided in Exhibit 99.1.
Rockwell Medical entered into an amendment to its Asset Purchase Agreement with Evoqua Water Technologies LLC, which extends the payment schedule for deferred payments and includes a partial reduction in one installment. The company also reconfirmed its 2024 gross margin guidance during a recent industry conference.
🚩 Red Flags
- Extension of payment schedules for deferred liabilities suggests potential liquidity management/cash flow constraints.
- Reliance on non-GAAP financial measures (Adjusted Gross Margin) to present core operating performance.
📋 Key Facts
- Amendment No. 1 to the Asset Purchase Agreement with Evoqua Water Technologies LLC was executed on July 12, 2024.
- The first deferred payment of $2,500,000 will be reduced by $322,260 (reimbursement for expenses) to a net total of $2,177,740, payable in four quarterly installments through April 2025.
- A second deferred payment of $2,500,000 will be paid in four quarterly installments from July 10, 2025, through April 10, 2026.
- CEO Mark Strobeck reconfirmed 2024 gross margin guidance between 14% and 16%.
- The company uses a non-GAAP 'adjusted gross margin' measure that excludes deferred revenue.
Rockwell Medical, Inc. held its 2024 Annual Meeting of Stockholders on May 21, 2024. The meeting resulted in the election of two Class III directors and the ratification of EisnerAmper LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on May 21, 2024.
- Robert S. Radie elected to the Board of Directors (Class III) with 11,524,139 votes 'For'.
- Mark Strobeck, Ph.D. elected to the Board of Directors (Class III) with 11,517,800 votes 'For'.
- Advisory vote on executive compensation approved with 11,126,598 votes 'For'.
- Ratification of EisnerAmper LLP as independent registered public accounting firm for 2024 received 19,446,483 votes 'For'.
Rockwell Medical, Inc. filed an 8-K to furnish an updated corporate presentation dated May 14, 2024. This is a routine disclosure under Item 7.01 (Regulation FD Disclosure) and does not contain material financial changes or structural shifts.
📋 Key Facts
- The filing was made on May 14, 2024.
- The company furnished an updated corporate presentation as Exhibit 99.1.
- The disclosure is intended to satisfy Regulation FD requirements.
Rockwell Medical, Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results were announced via press release on May 14, 2024.
- The report covers the fiscal quarter ending March 31, 2024.
Rockwell Medical, Inc. filed an 8-K to furnish an updated corporate presentation dated March 21, 2024. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The filing was made on March 21, 2024.
- The company furnished an updated corporate presentation as Exhibit 99.1.
- The information in the presentation is not considered 'filed' for purposes of Section 18 liability under the Exchange Act.
Rockwell Medical, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ending December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of earnings results (Item 2.02).
- Financial results cover the quarter and fiscal year ended December 31, 2023.
- Results were released via press release on March 21, 2024.
Rockwell Medical, Inc. filed an 8-K to furnish an updated corporate presentation dated January 8, 2024.
📋 Key Facts
- The company released an updated corporate presentation (Exhibit 99.1) on January 8, 2024.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Information provided in the exhibit is furnished rather than filed for purposes of Section 18 liability.
Rockwell Medical, Inc. entered into a Third Amendment to and Restatement of its Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP on January 1, 2024. The restructuring involves an $8.0 million term loan with interest-only payments for up to 36 months and the issuance of warrants to purchase common stock.
🚩 Red Flags
- High interest rate environment (Prime + 3.50%) and significant prepayment penalties suggest high cost of capital.
- Revenue-based financial covenants create risk of technical default if hemodialysis product sales underperform projections.
- Liquidity covenant tied to 'cash burn' indicates the company is likely in a cash-consuming phase.
- Issuance of warrants to a lender can lead to future dilution for existing shareholders.
📋 Key Facts
- Restructured Term Loans: Aggregate outstanding principal is $8.0 million as of January 1, 2024.
- Interest Terms: Interest rate is the greater of Prime Rate or 7.50%, plus a 3.50% margin; interest-only payments for 30–36 months.
- Warrant Issuance: Issued a warrant to Innovatus for 191,096 shares of common stock at an exercise price of $1.83 per share.
- Financial Covenants: Includes revenue-based covenants (must maintain 85% or 80% of projected hemodialysis product sales) and liquidity covenants (minimum liquidity must cover 3 months of cash burn or specific lease/cash requirements).
- Prepayment Penalties: Significant prepayment fees apply, including a Final Fee of 4.375% if not previously paid.